Potential new cardiovascular risk factors: Left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen

Annals of Internal Medicine

Volumn 131, Issue 5, 1999, Pages 376-386

  Harjai, Kishore J ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY RISK; FIBRINOGEN METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTRIGLYCERIDEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT;

EID: 0033533591     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-5-199909070-00009     Document Type: Review

References (168)

1. Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda Conference matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol. 1996;27:978-90.
2. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157:2413-46.
3. American Heart Association. Heart and Stroke Facts: Statistical Supplement 3 volumes. Dallas: American Heart Assoc, 1993-1995.
4. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA. 1993;269:3002-8.
5. Levy D, Andersen KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med. 1988;108:7-13.
6. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-27.
7. LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med. 1997;157:961-8.
8. Tato F, Vega GL, Grundy SM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients. Role of cholesterol-ester transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Thromb Vase Biol. 1997;17: 56-63.
9. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992;152:28-34.
10. Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J. 1993;69:338-42.
11. Genest J Jr. Cohn JS. Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol. 1995;76:8A-20A.
12. Savage DD. Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J 3d, et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study. Circulation. 1987;75(1 Pt 2):126-33.
13. Devereux RB, Pini R, Aurigemma GP, Roman MJ. Measurement of left ventricular mass: methodology and expertise [Editorial]. J Hypertens. 1997; 15:801-9.
14. Pearson AC, Gudipati C, Nagelhout D, Sear J, Cohen JD, Labovitz AJ. Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension. J Am Coll Cardiol. 1991;17 422-30.
15. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation. 1988;78:951-6.
16. Post WS, Larson MG, Myers RH, Galderisi M, Levy D. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension. 1997;30:1025-8.
17. Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation. 1991;83:13-25.
18. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-8.
19. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-6.
20. Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA, et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study, JAMA. 1994;272:33-6.
21. Devereux RB, Agabiti-Rosei E, Dahlof B, Gosse P, Hahn RT, Okin PM, et al. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens Suppl. 1996;14: S95-S101.
22. Keren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-52.
23. Devereaux RB. Regression of left ventricular hypertrophy. How and why? [Editorial] JAMA. 1996;275:1517-8.
24. Ghali JK, Liao Y, Cooper RS. Left ventricular hypertrophy in the elderly. American Journal of Geriatric Cardiology. 1997;6:38-49.
25. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension A meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-13.
26. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 1997;95:2007-14.
27. Ofili EO, Cohen JD, St Vrain JA, Pearson A, Martin TJ, Uy ND, et al. Effect of treatment of isolated systolic hypertension on left ventricular mass. JAMA. 1998;279:778-80.
28. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
29. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol. 1996;78:61-5.
30. Finkelstein JD. Methionine metabolism in mammals. Journal of Nutritional Biochemistry. 1990;1:228-37.
31. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis. 1995;116:147-51.
32. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-28.
33. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)me and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-81.
34. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-55.
35. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwalt HC, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-15.
36. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-6.
37. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-57.
38. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704-9.
39. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
40. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller I. Homocyst(e)ine and the risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vase Biol. 1997;17:1947-53.
41. Folsom AR, Nieto J, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1998;98:204-10.
42. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow R, Terry P, Tishler PV, et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 1996;15:136-43.
43. Woo KS, Chook P, Lolin Yl, Cheung AS, Chan LT, Sun YY, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997;96:2542-4.
44. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77: 1370-6.
45. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med. 1974;291:537-43.
46. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:6369-73.
47. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J. 1997; 11:1157-68.
48. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993; 91:303-18.
49. Harpel PC, Chang VT, Berth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A. 1992;89:10193-7.
50. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775-81.
51. Ubbink JB. The role of vitamins in the pathogenesis and treatment of hyperhomocyst(e)inaemia. J Inherit Metab Dis. 1997;20:315-25.
52. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998;338:1009-15.
53. Brattström LE, Israelsson B, Jeppesen JO, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest. 1988;48:215-21.
54. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81:51-60.
55. 6 supplements in elderly people with normal serum vitamin concentrations. Lancet. 1995;346:85-9.
56. Giri S, Thompson PD, Taxel P, Contois JH, Otvos J, Allen R, et al. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis. 1998;137:359-66.
57. Mijatovic V, Kenemans P, Netelenbos C, Jakobs C, Popp-Snijders C, Peters-Muller ER, et al. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril. 1998;69:876-82.
58. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med. 1991;115:209-18.
59. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990;10:240-5.
60. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-92.
61. Naruszewicz M, Selinger E, Davignon J. Oxidative modification of lipoprotein(a) and the effect of beta-carotene. Metabolism. 1992;41:1215-24.
62. Riis Hansen P, Kharazmi A, Jauhianen M, Ehnholm C. Induction of oxygen free radical generation in human monocytes by lipoprotein(a). Eur J Clin Invest. 1994;24:497-9.
63. Grainger DJ, Kirschenlohr M, Metcalfe JC, Weissberg PL, Wade OP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-8.
64. Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation. 1997;96:2514-9.
65. Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas JM, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation. 1994;90:1688-95.
66. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271:999-1003.
67. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990;301:1248-51.
68. Genest J Jr, Jenner JL, McNamara JR, Ordovas JM, Silverman SR, Wilson PW, et al. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol. 1991;67:1039-145.
69. Budde T, Fechtrup C, Bosenberg E, Vielhauer C, Enbergs A, Schulte H, et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 1994;14:1730-6.
70. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-65.
71. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. 1996;276:544-8.
72. Sandkamp M, Funke H, Schulte H, Kohler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 1990;36:20-3.
73. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins(a), Al, and B and parental history in men with early onset ischaemic heart disease. Lancet. 1988;1:1070-3.
74. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802.
75. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994;24:444-53.
76. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-4.
77. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91:1403-9.
78. Zenker G, Koltringer P, Bone G, Niedorkorn K, Pfeiffer K, Jurgen G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1989;17:942-5.
79. Chambless LE, Shahar E, Sharrett AR, Heiss G, Wijnberg L, Paton CC, et al. Association of transient ischemic attack/stroke symptoms assessed by standardized questionnaire and algorithm with cerebrovascular risk factors and carotid artery wall thickness. The ARIC Study, 1987-1989. Am J Epidemiol. 1996;144:857-66.
80. van Kooten F, van Krimpen J, Dippel DW, Hoogerbrugge N, Koudstaal PJ. Lipoprotein(a) in patients with acute cerebral ischemia. Stroke. 1996;27:1231-5.
81. Solymoss BC, Mardi M, Wesolowska E, Lesperance J, Pelletier LC, Campeau L. Risk factors of venous aortocoronary bypass graft disease noted at late symptom-directed angiographic study. Can J Cardiol. 1993;9: 80-4.
82. Barbir M, Kushwaha S, Hart B, Macken H, Thompson GR, Mitchell A, et al. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet. 1992;340:1500-2.
83. Orth-Gomer K, Mittleman MA, Schenk Gustafsson K, Wamala SP, Eriksson M, Belkic K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation. 1997;95:329-34.
84. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R. Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 1996;16:471-8.
85. Schreiner PJ, Chambless LE, Brown SA, Watson RL, Toole J, Heiss G. Lipoprotein(a) as a correlate of stroke and transient ischemic attack prevalence in a biracial cohort: the ARIC Study. Atherosclerosis Risk in Communities. Ann Epidemiol. 1994;4:351-9
86. Dhawan J. Coronary heart disease risks in Asian Indians. Curr Opin Lipidol. 1996;7:196-8.
87. Sunayama S, Daida H, Mokuno H, Miyano H, Yokoi H, Lee YJ, et al. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women > or = 55 years of age. Circulation. 1996;94:1263-8.
88. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-33.
89. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-9.
90. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA. 1995;273:1269-73.
91. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis, 1991;89:59-67.
92. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol. 1998;31:519-25.
93. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol. 1995;15:850-5.
94. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vase Biol. 1996;16:1568-72.
95. Albers JJ, Marcovina SM. Lipoprotein(a) quantification: comparison of methods and strategies for standardization. Curr Opin Lipidol. 1994;5:417-21.
96. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med. 1997;157:1170-6.
97. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771-4.
98. Temme EH, Mensink RP, Hornstra G. Comparison of the effects of diets enriched in lauric, palmitic, or oleic acids on serum lipids and lipoproteins in healthy women and men. Am J Clin Nutr. 1996;63:897-903.
99. Thomas TR, Ziogas G, Harris WS. Influence of fitness status on very-low-density lipoprotein subfractions and lipoprotein(a) in men and women. Metabolism. 1997;46:1178-83.
100. Marcovina SM, Kennedy H, Bittolo Bon G, Cazzolato G, Galli C, Casiglia E, et al. Fish intake, independent of apo(a) gene expression, accounts for plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: the Luglawa Study. Arterioscler Thromb Vasc Biol. 1999;19:1250-6.
101. Espeland MA, Marcovina SM, Miller V, Wood PD, Wasilauskas C, Sherwin R, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation. 1998;97:979-86.
102. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB Jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293-301.
103. Keilani T, Schleuter WA, Levin ML, Batlle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med. 1993;118:246-54.
104. Gavish D, Breslow JL. Lipoproteinta) reduction by N-acetylcysteine. Lancet. 1991;337:203-4.
105. NIH consensus conference. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. JAMA. 1993;269:505-10.
106. Brenner H, Heiss G. The intraindividual variability of fasting triglyceride - a challenge for further standardization. Eur Heart J. 1990;11:1054-8.
107. Hokanson JE, Autsin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-9.
108. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520-5.
109. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-8.
110. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-36.
111. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 1996;16: 697-704.
112. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 1990;81: 470-6.
113. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention study Eur Heart J. 1998:19 Suppl H:H42-7.
114. de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J. 1996;17 Suppl:37-42.
115. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-8.
116. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heat disease. JAMA. 1984;251:351-64.
117. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45.
118. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91:2488-96.
119. Jialal I, Scaccini C. Antioxidants and atherosclerosis. Curr Opin Lipidol. 1992;3:324-8.
120. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low-density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherosclerosis. Proc Natl Acad Sci U S A. 1987;84:2995-8.
121. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its athero-genicity. N Engl J Med. 1989;320:915-24.
122. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med. 1986;314:488-500.
123. Morris DL, Kritchevsky SB, Davis CE. Serum carotenoids and coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. JAMA. 1994;272:1439-41.
124. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-6.
125. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-9.
126. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992;3:194-202.
127. Kushi LH, Folsom AR, Pinneas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996;334:1156-62.
128. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029-35.
129. Omenn GS, Goodman GE, Thronquist MD, Balmes J, Cullen MR, Glass A, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996;88: 1550-9.
130. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145-9.
131. The Women's Health Study: summary of the study design. Women's Health Study Research Group. Journal of Myocardial Ischemia. 1992;4:27-9.
132. Stephens SG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996,347:781-6.
133. Hodis HN, Mack WJ, LaBree L, Hemphill LC, Azen SP. Natural antioxidant vitamins reduce coronary artery lesion progression as assessed by sequential coronary angiography [Abstract]. J Am Coll Cardiol. 1994;23:481A.
134. Hodis HN, Mack WJ, Olan D, Lin C, Lin Ci-hua, Seranian A, et al. Antioxidant vitamin intake reduces progression of carotid artery intima media thickness. Circulation. 1996;94 Suppl 1:1508.
135. Manson JE, Gaziano JM, Spelsberg A, Ridker PM, Cook NR, Buring JE, et al. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. Ann Epidemiol. 1995;5:261-9.
136. Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. 1995;61(6 Suppl):1402S-6S.
137. Rapp JH, Connor WE, Lin DS, Porter JM. Dietary eicosapentaenoic acid and docosahexaenoic acid from fish oil. Their incorporation into advanced human atherosclerotic plaques. Arterioscler Thromb. 1991;11:903-11.
138. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2: 757-61.
139. Rimm EB, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med. 1996;125:384-9.
140. Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol. 1997;30:855-62.
141. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med. 1997; 337:365-72.
142. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-9.
143. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-5.
144. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA. 1987;258:1183-6.
145. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, et al. Fibrinogen, viscosity and white blood cell counts are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 1991;83:836-44.
146. Heinrich J, Balleisen L, Schulte H, Assmann G. van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-9.
147. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-63.
148. Lowe GD, Drummond MM, Lorimer AR, Mutton I, Forbes CD, Prentice CR, et al. Relation between the extent of coronary artery disease and blood viscosity. BMJ. 1980;280:673-4.
149. Broadhurst P, Kelleher C, Hughes I, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis. 1990;85:169-73.
150. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-7.
151. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 1995;92:31-8.
152. Rosengren A, Wilhelmsen L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and nonsmokers. The Study of Men Born in 1933. J Intern Med. 1996;230:499-507.
153. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation. 1997;96:4204-10.
154. Behar S. Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention. Blood Coagul Fibrinolysis. 1999;10 Suppl 1:S41-3.
155. Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res. 1994;73:1-19.
156. Smith EB, Crosbie L. Does lipoprotein(a) (Lp(a)) compete with plasminogen in human atherosclerotic lesions and thrombi? Atherosclerosis. 1991;89: 127-36.
157. Barasch E, Benderly M, Graft E, Behar S, Reicher-Reiss H, Caspi A, et al. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. J Clin Epidemiol. 1995;48:757-65.
158. Brunner E, Smith GD, Marmot M, Canner R, Beksinska M, O'Brien J. Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet. 1996;347:1008-13.
159. Muldoon MF, Herbert TB, Patterson SM, Kameneva M, Raible R, Manuck SB. Effects of acute psychological stress on serum lipid levels, hemoconcentration, and blood viscosity. Arch Intern Med. 1995;155:615-20.
160. Meade TW, North WR, Chakrabarti R, Haines AP, Stirling Y. Population-based distributions of haemostatic variables. Br Med Bull. 1977;33: 283-8.
161. Ernst E, Resch KL. Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J. 1995;16 Suppl A:47-53.
162. Pazzucconi F, Mannucci L, Mussoni L, Gianfranceschi G, Maderna P, Werba P, et al. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. Eur J Clin Pharmacol. 1992;43:219-23.
163. Niort G, Bulgarelli A, Cassader M, Pagano G. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenaemic patients. Atherosclerosis. 1988;71:113-9.
164. Otto C, Pschiere V, Schwandt P, Richter WO. Effect of gemfibrozil treatment on plasma fibrinogen levels in patients with familial hypertriglyceridaemia [Abstract]. Blood Coagul Fibrinolysis. 1994;5 Suppl 2:11.
165. De Maat MP, Knopscheer HC, Kastelein JJ, Kluft C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia [Abstract]. Blood Coagul Fibrinolysis. 1994;5 Suppl 2:17.
166. Koenig W, Hoffmeister HCA, Nehmer C, Sund M, Staub JP, Wolf C, et al. How do fibrates lower fibrinogen? The possible role of interleukin-6 suppression [Abstract]. Blood Coagul Fibrinolysis. 1994;5 Suppl 2:16.
167. Drouet L, Mazoyer E, Ripoll L, Dosquet C, Tobelem G. Does the fall in plasma fibrinogen during ticlopidine treatment depend on the initial level? [Abstract] Blood Coagul Fibrinolysis. 1994;5 Suppl 2:18.
168. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999;130:933-7.